Clinical Trials Logo

Circulating Tumour DNA clinical trials

View clinical trials related to Circulating Tumour DNA.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05227261 Recruiting - Cancer, Breast Clinical Trials

Early Detection of Five Common Cancers Using the ctDNA Analysing Test

K-DETEK
Start date: April 10, 2022
Phase:
Study type: Observational

This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA). Primary objective: To evaluate the performance characteristics of the blood ctDNA test in early detecting cancers. Secondary objectives: - To evaluate the performance characteristics of the test in determining the origin of tumour, as compared to the findings of the imaging diagnostic tests. - To determine the risk of cancers development in the high-risk population, as compared to that in the moderate-risk group.

NCT ID: NCT03644303 Recruiting - Prostate Cancer Clinical Trials

Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.

TRAP
Start date: August 13, 2018
Phase: N/A
Study type: Interventional

This multi-center, phase II trial will be conducted in men with castration resistant prostate cancer. The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT) can slow down the growth of metastatic prostate cancer. If SBRT is effective it will represent a new treatment option in these patients, providing more prolonged control without having to resort to chemotherapy and its potentially unpleasant side effects. In this trial, the investigators will identify men who, despite being on next generation androgen deprivation treatment (Abiraterone or Enzalutamide) have developed one or two new sites of worsening (growing) disease but the rest of their cancer is still responding to hormonal therapy. If it is the case that SBRT can successfully treat the cancer which is resistant to current treatment then the investigators hope they will be able to better control the spread of cancer in these patients for longer. The investigators also hope that they will be able to use the tell-tale products (gene markers) that are released into the bloodstream in these patients, or identify characteristics on novel imaging such as magnetic resonance imaging (MRI) to help identify patients in the future who will benefit the most.